


CONSENSUS STATEMENTS

Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with up-to-date information on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees selection of relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integrity of the process. The statements are derived from evidence-based medicine whenever possible and the panel offers interpretive comments when such evidence is inadequate or contradictory. A draft is prepared by the panel, checked by KH followed by solicitation of input by the ACVIM membership which may be incorporated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it is edited before publication. The authors are solely responsible for the content of the statements.

Management of *Coxiella burnetii* infection in livestock populations and the associated zoonotic risk: A consensus statement

Paul J. Plummer¹  | J. Trenton McClure² | Paula Menzies³ | Paul S. Morley^{4,5} | René Van den Brom⁶ | David C. Van Metre⁴

¹Department of Veterinary Diagnostic and Production Animal Medicine and the Department of Veterinary Microbiology and Preventative Medicine, College of Veterinary Medicine, Iowa State University, Ames, Iowa

²Department of Health Management, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, Prince Edward, Canada

³Department Population Medicine, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada

⁴Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado

⁵Colorado School of Public Health, Fort Collins, Colorado

⁶GD Animal Health, Deventer, The Netherlands

Correspondence

Paul J. Plummer, Iowa State University, Veterinary Diagnostic and Production Animal Medicine, Veterinary Microbiology and Preventative Medicine, Iowa State University College of Veterinary Medicine, Ames, Iowa. Email: pplummer@iastate.edu

Infections caused by *Coxiella burnetii*, commonly referred to as coxiellosis when occurring in animals and Q fever when occurring in humans, are an important cause of abortions, decreased reproductive efficiency, and subclinical infections in ruminants. The organism also represents an important zoonotic concern associated with its ability to aerosolize easily and its low infectious dose. Available diagnostic tests have limited sensitivity, which combined with the absence of treatment options in animals and limited approaches to prevention, result in difficulty managing this agent for optimal animal health and zoonotic disease outcomes. The purpose of this consensus statement is to provide veterinarians and public health officials with a summary of the available information regarding management of *C. burnetii* infection in livestock populations. A discussion of currently available testing options and their interpretation is provided, along with recommendations on management practices that can be implemented on-farm in the face of an outbreak to mitigate losses. Emphasis is placed on biosecurity measures that can be considered for minimizing the zoonotic transmission risk in both field and veterinary facilities.

KEYWORDS

abortion, *Coxiella burnetii*, coxiellosis, Q fever, shedding, zoonotic

Abbreviations: BTM, bulk tank milk; CFT, complement fixation test; ELISA, enzyme linked immunosorbent assay; IFA, immunofluorescence assay; Q fever, query fever; qPCR, quantitative PCR; SCV, small cell variant

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2018 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.

1 | INTRODUCTION

Query fever, (Q fever) was first described as a febrile illness of abattoir workers in Australia in 1937.¹ Subsequently, the causative agent was identified as *Coxiella burnetii*, a ubiquitous, small, pleomorphic,

intracellular Gram-negative bacterium.^{2,3} Infections principally occur through inhalation or ingestion, although infection by blood transfusion occurs.^{4,5} Infections in animals are termed coxiellosis. Coxiellosis occurs in a variety of species, with domestic ruminants serving as the most important reservoir for human infection. Coxiellosis is frequently subclinical, with clinical disease manifesting most commonly in small ruminants as late-term abortion, stillbirth, and birth of weak offspring and rarely as abortion or reproductive failure in cattle. Placental membranes, fetuses, and uterine fluids from clinically affected animals can contain massive numbers of *C. burnetii*; however, the agent can be shed in large numbers during parturition in clinically unaffected animals.⁶ The organism replicates within the trophoblasts of the placenta and after the logarithmic growth phase, produces a spore-like bacterial form termed a small cell variant (SCV)⁷; these SCVs are responsible for persistence of the organism in dust, manure, and the air of farms.^{8–13} Aerosols originating from infected farms can act as a source of infection for humans.^{12,14,15}

In this document, we define coxiellosis-positive herds as those with evidence of infection (identification of *C. burnetii* or its DNA in biological samples obtained from livestock), which might or might not result in clinical disease and shedding in individual animals. While serologic testing cannot rule-out infection, in most cases it alone is not sufficient to document coxiellosis at the herd level, and additional testing focused on documenting the presence of the organism is warranted. At the individual animal level, evidence of infection with the organism, with or without clinical disease would be considered coxiellosis; however, the extent and duration of shedding is unpredictable in affected animals.

Query fever and coxiellosis are considered to be re-emerging diseases in many countries. Recently, outbreaks of abortion in sheep and goats with concurrent human illness have occurred worldwide.^{16–20} Although human infections are often asymptomatic or mild, debilitating complications can occur.

There are several relevant publications available for human and veterinary health professionals, which provide guidance for livestock and public health concerns related to *C. burnetii*. These are summarized in Table 1. The objective of this consensus statement is to complement these documents and to provide more focused recommendations—based on the literature and expert opinion—regarding the clinical management of animals on premises with confirmed or suspected coxiellosis. These recommendations focus primarily on ruminants; however, pertinent discussions are also included related to companion animals, horses, and wildlife. Specific questions addressed in this statement include:

1. How can coxiellosis be most accurately diagnosed at the herd/flock level with consideration of the individual animal level?
2. How can infected herds and flocks be managed to control clinical and subclinical disease, including shedding of the agent and transmission to other herds and flocks?
3. How can the zoonotic risks be mitigated?

2 | DIAGNOSIS OF *C. BURNETII* IN INDIVIDUAL ANIMALS

To determine the presence or freedom of infection because of *C. burnetii* in livestock operations, the strengths and limitations of diagnostic tests in various clinical scenarios must be understood. Diagnostic tests detect either the agent (Table 2) or immunological evidence of previous exposure (Table 3) to *C. burnetii*.

A number of commercial PCR kits are available for *C. burnetii* DNA detection. A commonly used target gene is *IS1111*, which is present in multiple copies on the genome, but varies in the exact copy number by genotype.^{28,29} A commercial European kit uses the *GAPDH* gene target.²⁶ When warranted, molecular based bacterial genotyping can be performed to gain insights into the epidemiology and pathogenicity of the isolate.

A positive antibody titer is evidence of current or previous infection with *C. burnetii*, but is not necessarily indicative of current or prior shedding or disease. Importantly, seronegative animals (regardless of test used) can be actively shedding the organism.³⁰ Serologic tests evaluate antibodies to two distinct antigenic forms of *C. burnetii* called phase I and phase II.³¹ Most commercially available antibody tests for livestock detect the summative titer to phase I and phase II antibodies. Data in humans suggest that when independently analyzed, phase II antibodies indicate an acute infection when found in higher titers than phase I antibodies.²² However, phase-specific antibody testing in livestock remains poorly characterized at present.

Enzyme linked immunosorbent assay (ELISA) is preferred for large-scale screening of the infection status livestock.²⁴ The CHEKIT Q Fever Antibody ELISA, (IDEXX Laboratories, Inc) is based on *C. burnetii* purified antigens of the 9-Mile tick-sourced strain.³² It can be used on serum, plasma and milk of ruminants. The manufacturer claims 100% sensitivity and 100% specificity based on tests performed on 81 samples of animals with known infection status. In Europe, the LSIVET Ruminant Milk/Serum Q fever (Laboratoire Service International, Lissieu, France) is an ELISA test using an ovine-derived antigen.³³ Sensitivity is estimated to be 85% and specificity at

TABLE 1 Publications that augment and synergize with this consensus statement

Focus	Title	Affiliation
Guidance for a Coordinated Public Health and Animal Health Response	Prevention and Control of <i>Coxiella burnetii</i> Infection among Humans and Animals: Guidance for a Coordinated Public Health and Animal Health Response, 2013 ²¹	National Association of State Public Health Veterinarians and the National Assembly of State Animal Health Officials
Human Q Fever Diagnosis and Epidemiology	Diagnosis and Management of Q Fever – United States, 2013 Recommendations from CDC and the Q Fever Working Group ²²	US Centers for Disease Control and its affiliate Q Fever Working Group
US Risk Assessment of Large-Scale Outbreak in Goats	Evaluation of Factors that Would Initiate or Propagate Epidemic Coxiellosis in the United States. Domesticated Goat Population ²³	USDA Centers for Epidemiology and Animal Health

TABLE 2 Summary of diagnostic test used for detection of evidence of infection with *C. burnetii*

Test	Diagnostic specimen	Considerations ^a
Direct Observation of Bacteria	Placental membranes with at least 1–2 cotyledons, fetal tissues, and vaginal mucous	<ul style="list-style-type: none"> • Pinkish red coccobacillary; usually intracellular bacteria on modified Ziehl-Neelsen, Gimenez, and Giemsa stains.²⁴ • Confirm by immunohistochemistry testing²⁴
Polymerase Chain Reaction	Abortive tissues, individual and BTM and milk products, feces, vaginal mucus, and environmental samples	<ul style="list-style-type: none"> • PCR generally indicates presence of DNA from live or bacteria, from infection or contamination.²⁵ • qPCR allows for better interpretation of the significance of results: < 1000 gene copies of IS1111/μL is not generally considered a significant result.^{26,27} • Sensitivity and specificity of the test depend on the gene target of the assay. • PCR on blood may augment, but should not replace other methods of testing as sensitivity is not known.
Bacterial culture	Abortive tissues, individual and BTM and milk products, fecal material, vaginal mucus, and environmental samples	<ul style="list-style-type: none"> • Rarely performed because of human health risk and fastidious growth requirements of the organism. • Must be done in Biosafety Level 3 laboratory. • Requires relatively high levels of shedding to be reliably cultured.

^a Positive results may need to be reported to local public and/or animal health officials.

95%.³⁴ Phase-specific ELISAs have been developed but are not widely available for clinical application.³¹

Although infection with *C. burnetii* does stimulate cell mediated immunity (CMI), diagnostic testing of CMI is not commercially available. In one study, the interferon-gamma assay did not differentiate between exposed and non-exposed goats.²⁸ Additional research regarding CMI testing for diagnosis of coxiella infections is needed.

3 | DIAGNOSIS OF *C. BURNETII* INFECTED HERDS AND FLOCKS

Subclinical infection with *C. burnetii* in ruminants is far more common than clinical infection. This creates a challenge in arriving at the correct diagnosis when investigating abortion outbreaks, trying to assess zoonotic risk, or determining freedom from infection in individuals or groups of animals. Most animals that abort because of *C. burnetii* infections are not systemically ill.⁶ Coxiella-associated abortion outbreaks with >10% attack rates during the lambing/kidding season of a flock or herd are not uncommonly reported in small ruminants. Neonates can also be born alive but weak during abortion outbreaks.⁶ In cattle, abortion is uncommon, although it has been hypothesized that there is an association between reproductive failure and infection.³⁵

3.1 | Investigating *C. burnetii* as the cause of abortion

When investigating the cause of abortion, both the placenta and the aborted fetuses should be examined. Severe placentitis is frequently present in small ruminants affected by *C. burnetii* infections. Extracellular and intracellular organisms are usually visible in large numbers when direct smears of cotyledon tissues and histopathological sections are examined microscopically.^{24,36,37} Lesions in the placenta of cows that abort because of *C. burnetii* infections are typically much milder.²⁶ Quantitative PCR (qPCR) results can be helpful when determining if *C. burnetii* is the most likely cause of the abortion in small ruminants, rather than simply being concurrently shed or representing environmental contamination. Animals with abortion caused by *C. burnetii* tend to have qPCR Ct values that correspond to several orders of magnitude greater quantities of organisms (eg, 10⁹–10¹⁰ copies/μL) than those associated with asymptomatic long-term shedding or environmental contamination.^{38,39} In cases of abortion with *C. burnetii*, fetal tissues (liver, abomasal fluid, and lung) can also be PCR-positive. High numbers of organisms as evidenced by qPCR values combined with histopathologic placental lesions provide strong evidence that the abortion is caused by *C. burnetii*. However, identification of PCR-positive samples regardless of the quantity of organisms detected should trigger a discussion of the zoonotic implications of the findings and evaluation of the biological risk it entails.

TABLE 3 Summary of diagnostic test used for detection of evidence of exposure to *C. burnetii*

Test	Diagnostic specimen	Considerations ^a
ELISA	Serum	<ul style="list-style-type: none"> • Preferred for large scale screening of livestock.²⁴ • Good agreement with IFA results.
Immunofluorescence Assay (IFA)	Serum	<ul style="list-style-type: none"> • Definitive serological test in human medicine. • Less widely utilized in veterinary medicine due technical requirements. • Very good agreement with ELISA.
Complement Fixation Test (CFT)	Serum	<ul style="list-style-type: none"> • Less sensitive than most ELISA (as low as 10% in aborting animals); good specificity (>98%).^{17–19} • Negative ELISA samples may show low CFT titres, possibly detecting IgM.¹⁵ • Limited utility in livestock.

^aWith all serological tests listed, seronegative animals may shed the organism.

3.2 | Patterns of shedding in aborting herds/flocks

Before aborting, shedding of bacteria in vaginal fluids is absent or minimal, even when bacterial counts *in utero* are substantial.⁶ This limits the utility of using PCR as a prepartum assessment of an animal's risk of abortion or post-partum shedding. However, bacterial shedding patterns change dramatically at abortion or parturition. After aborting, bacterial shedding can be detected by PCR in vaginal mucus, feces, and milk, but patterns of shedding are different among species. In cattle, vaginal shedding of *C. burnetii* is typically very short (<14 days) while shedding in milk occurs for much longer periods.⁴⁰ Among infected goats during the first month postpartum, the proportion of does shedding in milk, feces or vaginal mucus is similar for individuals that abort and those that kid normally (30%–50%).⁴¹ Milk shedding patterns in goats are similar to vaginal shedding but with lower numbers of pathogens and for longer periods (8 weeks or more).^{6,41–43} The level of vaginal shedding typically decreases by 2–3 weeks postkidding.³¹

3.3 | Abortion, serological response, and shedding

Sheep and goats that abort are usually seropositive at the time of abortion, although titers can decrease with time.^{31,44} However, infected, seropositive herd-mates can undergo normal parturition and deliver healthy offspring.³² Additionally, seronegative small ruminants can have PCR-positive vaginal swabs after parturition.⁴⁴ During outbreaks of coxiellosis, aerosol contamination of sampling supplies because of high environmental load can occur and lead to false positive test in pathogen detection.

3.4 | Herds or flocks infected with *C. burnetii* in the absence of abortions—shedding patterns

It is common to encounter herds or flocks where bacteria are being shed without any history of abortion or other abnormal reproductive events.^{30,45–47} In such cases, the numbers of organisms being shed is typically much lower than is seen in aborting animals, but the proportion of animals shedding can still be as high as 90%–100%.³⁰ Shedding is common in birth fluids, vaginal mucus, milk, and feces but the relative quantity of bacteria shed in these bodily fluids differs by species in a pattern similar to that of aborting herds/flocks.^{30,45–47}

3.5 | Serological status and shedding

In dairy cattle, seroconversion tends to occur within the first ninety days of lactation, with young multiparous cattle being the most likely to seroconvert.^{35,48} Serologic status of individual cows is moderately predictive of shedding status. Approximately 65% of cows with PCR-positive milk samples remain seronegative.³⁰

Similarly, in small ruminants, there is poor correlation between risk of bacterial shedding and serological status. Among sheep and goats that shed *C. burnetii* by any route, the proportion of seropositive sheep is low (<10%) and moderate in goats (~50%).³⁰ A high proportion of goats shedding at parturition will be seronegative one month later and in contrast, a high proportion of non-shedding goats are frequently seropositive.^{39,47,49–51}

3.6 | Bulk tank milk (BTM) testing and herd/flock status

Immunological testing of BTM has been evaluated as a means to evaluate the likelihood of previous infection and the risk shedding bacteria in healthy dairy herds. In dairy cattle, PCR based BTM testing results for a given herd generally provide consistent results over time.²⁶ BTM antibody concentrations in that species is strongly predictive of within-herd seroprevalence; detection of a within-herd prevalence of >20% is possible with a BTM ELISA.⁵² There appears to be good agreement between seroprevalence and BTM antibody concentration in dairy sheep flocks.⁵³ As such, BTM ELISA is a useful test for large-scale screening programs to detect flocks that have been previously infected, although BTM PCR may be more sensitive for detection of actively infected/shedding flocks.⁵³ In dairy goat herds, BTM ELISA also is similarly predictive of shedding status when measured with BTM PCR (cut-off 100 bacteria/mL milk) and also for detecting previously infected herds with seroprevalence of >15% (SP ratio of 43%).⁵⁴ Bulk tank milk containing >10⁵ *C. burnetii*/mL as estimated by qPCR is associated with herd seroprevalence of ≥50% in dairy cattle.³⁵

4 | LOW-RISK HERD/FLOCK STATUS FOR *C. BURNETII* INFECTION

It is often important to evaluate whether individuals or groups of animals have a low risk for shedding *C. burnetii*, such as when animals are used for teaching, research or when planning obstetrical procedures in clinical veterinary practice. As previously stated, serological testing of individual animals does not reliably predicting the likelihood of shedding in any species.⁴⁷ Detection of shedding by PCR can be used to determine current status; however, that shedding status can change rapidly.^{30,41} For example, a pregnant goat can be PCR-negative and seronegative immediately before parturition, but still shed bacteria during a normal parturition.^{30,41} The following recommendations are based on first principles of disease surveillance, the epidemiology of coxiellosis, and the accuracy of available diagnostic tests.

The infection status of the population is often used to make inferences regarding the status of individuals. Unfortunately, the best method for determining whether flocks or herds have a low likelihood of current or previous infection has not been well established. It is much easier to detect evidence of infection than it is to determine freedom from infection.⁵⁵ Given the zoonotic nature of coxiellosis, the practitioner needs to determine the level of risk that they are willing to assume with regard to their efforts to determine infection status. This decision process might differ because of the highly infectious and zoonotic nature of this organism. Flock-level status with *C. burnetii* is often subject to more rigorous proof of low to no risk of infection than other disease agents. Online calculators can be used to determine the percentage of the herd that needs to be sampled to achieve a reasonable confidence of detecting infection. (See the sample size and FreeCalc calculators at AusVet: <http://epitools.ausvet.com.au>). This resource also provides a calculator for estimating true prevalence when using imperfect tests. Also, see the sample size calculators for risk-based sampling and representative sampling.

If a small number of serologically positive animals (eg, <1%) are found in a herd where definitive determination of the herd level infection status is necessary because of regulatory or marketing requirements, further nonserologic testing can be performed to confirm the population's status. PCR may be performed on vaginal mucus, feces, environmental samples, or milk. Additionally, adult animals that are euthanized can be evaluated for *C. burnetii* by conducting PCR testing on female reproductive organs, liver, spleen, kidney, and lung.

As an alternative to serology, PCR can be used as a screening test. This can be done at the herd-level in dairy herds using BTM or in samples collected from individual animals. Data suggest that a single dairy goat shedding organisms in milk that is mixed with that from up to 25 000 other animals can be detected; as such, it is likely that low herd prevalence (eg, <0.001%) can be detected using this methodology.⁵⁶ However, use of repeated testing is always advisable in situations where knowing the status is critical. PCR is most sensitive on vaginal mucus in the first week postpartum.^{6,42} The possible role of *C. burnetii* in all abnormal parturient events, particularly those that are abortions or when stillbirth and weak neonates are present, should also be thoroughly investigated in herds/flocks that are trying to achieve or document a low-risk status. Abortions should be submitted to a diagnostic laboratory for routine investigation that includes qPCR of placental and fetal tissues, as well as histopathology of placenta. The veterinarian or owner might also want to submit randomly selected placental samples from normal parturitions for qPCR. Evaluation of blood by qPCR is not recommended as a screening test, as the magnitude and duration of bacteremia in ruminants are not well characterized.⁵⁷

Introduction of new animals to a herd, or movement of animals between different management groups of a farm can represent an important biosecurity risk to maintaining a low-risk herd status. Detection of infected animals with absolute certainty before their introduction to a herd or flock is not currently possible; however appropriate diagnostic screening, as discussed earlier, decreases the risk of disease introduction. New introductions should only come from herds where testing indicates a low risk of *C. burnetii* infection. Since *C. burnetii* can infect any species including all livestock, domestic animals and wildlife, the interface of the herd with these animals should be minimized to the extent possible. Location of the farm is critical; as organisms can be transmitted in airborne particles for 5 km or more, so it is suggested that a herd with low-risk status be located at least that far from other small ruminant operations.^{14,58} Strategies to mitigate spread of infection within and among farms and to humans are discussed later in this statement. Unfortunately, even when precautions are put in place to promote achieving or maintenance of low infection risk in a population, because of the ubiquitous nature of the organism, coxiellosis or detection of the organism during surveillance can still be warranted. A combination of good biosecurity, vaccination (where available), and early detection of shedding with appropriate management of infected animals appears to be the most appropriate way to maintain a low-risk population.

5 | SURVEILLANCE OF COXIELLOSIS IN CATTLE, SHEEP, AND GOAT FARMS

The main aim of surveillance for shedding of *C. burnetii* is to detect shedding in an early stage, so that environmental contamination and human exposure can be prevented or minimized. Based on the characteristics of the different tests, several PCR techniques seem most applicable for routine surveillance of shedding of *C. burnetii* in samples of different origin from domestic ruminants. Surveillance of shedding in dairy ruminants can be performed using BTM samples. Further research on testing of environmental and air samples is necessary before they are implemented into surveillance programs.^{29,59–62}

After a large human Q fever outbreak in the Netherlands, several compulsory disease control measures were implemented nationwide. A compulsory vaccination program in dairy goat herds was initiated, and its efficacy monitored using BTM PCR and surveillance for abortion. This control program allowed officials to certify individual herds as having a low-risk of coxiellosis, and to provide early detection of any change in herd status.⁶³

6 | CONTROL OF COXIELLOSIS

Several studies have investigated risk factors of coxiellosis in ruminants in the past decade.^{20,64–67} Factors that were associated with lower risk of seropositivity in ruminants in these studies included quarantine of new animals entering the farm, use of stringent hygiene measures for visitors, limited introduction of new animals, prompt removal of birth materials immediately postpartum, and frequent cleaning or changing of bedding. When attempting to control coxiellosis, the primary goal should be the reduction of zoonotic risk associated with shedding during an abortion event, during normal parturition, or through shedding in the milk and manure. The following control measures can be considered for achieving these goals.

6.1 | Vaccination

In portions the European Union, vaccination using a phase I killed *C. burnetii* vaccine (Coxevac, Ceva Sante Animale) is recommended for use in goats for reduction of abortion risk and shedding of *C. burnetii* in vaginal fluids, feces, and milk and in cattle for reduction of shedding. It has proven to be effective at reducing bacterial shedding levels (<200 organisms per vaginal sample in 24% of vaccinated animals) under experimental conditions, as well under field circumstances.^{3,68–71} The vaccine instructions are to administer to nonpregnant animals at least 3 weeks before breeding; ideally animals are initially vaccinated when young (goats at 3 months of age), 3 weeks later, and then followed by an annual booster vaccination. The effect on bacterial shedding is most pronounced in goats when vaccinated before their first pregnancy.⁶⁸ In contrast, vaccines developed from killed phase II (SCV) organisms did not affect the course of the disease or excretion.³ Reduced shedding in sheep after vaccination with a phase 1 vaccine during pregnancy has been reported.⁷² However, no reduced shedding was observed after vaccination during pregnancy in goats.⁶⁸ At the time of writing of this

consensus statement, there is not a commercially available phase I vaccine licensed and available in the US. The Canadian Food Inspection Agency has stated it will issue a biologic import permit allowing provisional use of a commercial phase I vaccine in Canadian herds and flocks when the need is demonstrated (personal communication P. Menzies).

6.2 | Antibiotic treatment to control abortion and shedding of *C. burnetii*

Overall, there is a lack of scientific evidence of efficacy of antimicrobial drugs when used in attempts to control abortion or shedding of *C. burnetii*. Because of this lack of evidence and the need to promote antimicrobial stewardship, it is the opinion of this consensus panel that antimicrobial drugs should not be used for control or treatment of coxiellosis. In vitro, *C. burnetii* is sensitive to several antimicrobial drugs, including tetracycline. In-feed administration of antimicrobial drugs do not reach target concentrations in reproductive tissues or the fetus.^{73,74} In the face of an outbreak, treatment with two successive injections of oxytetracycline during the last month of pregnancy has been proposed for use in goats.^{3,75} But to date, there are no well-controlled field trials demonstrating an evidence-based benefit of this intervention in goats.⁷⁶ The same treatment regimen has been evaluated in sheep, but our study also implemented concurrent vaccination and suffered from low statistical power, making interpretation of results difficult.⁷⁷ In cattle, antimicrobial treatment with injectable oxytetracycline was not associated with decreased shedding in milk.⁷¹ Another study suggested that a single treatment with oxytetracycline, administered at drying off, had no effect on the bacterial load.⁷⁸

6.3 | Expected clinical course at the herd-level

The most beneficial tool that has been described for management of clinical disease is the implementation of vaccination using phase I form of the killed bacteria.⁷⁹ Once coxiellosis is confirmed on a premises, infections should be considered endemic in the population.⁸⁰ Animal infection and shedding should generally be expected for multiple years to come, even in the face of intervention measures, including vaccination.⁵⁶ In cases of coxiellosis abortion storms, the rate of coxiellosis related abortions is likely to decrease after initial introduction, but shedding during normal parturition will continue.^{41,81} Despite the difficulty in eliminating the presence of the organism it is critical that measures are to decrease the environmental load and the related zoonotic infection risk.

6.4 | Controlling environmental contamination and transmission

The SCV of *C. burnetii* is profoundly resistant to environmental stress, desiccation, and most commonly used disinfectants. It can survive in the environment for prolonged periods of times (years to decades), and is readily aerosolized in dust.^{8,82,83} Based on epidemiologic data collected during the outbreak in the Netherlands, wind dispersion aerosols can result in dissemination of the disease for up to 5 km downwind of infected facilities.^{14,58} The greatest risk of aerosol

formation and subsequent human transmission appears to be linked with parturition of animals, especially sheep and goats.^{20,84} When small ruminant farms are endemically infected, measures should be taken to minimize the potential aerosol formation from highly infected materials. The presence of an abortion storm may increase this risk because of a higher proportion of animals shedding and should be addressed appropriately as described below.^{6,44,85}

Measures that can be implemented to control transmission, environmental contamination and consequently minimize zoonotic risk include:

- Segregate periparturient animals from other high-risk animals (gestating and young). This may decrease exposure to the high level or organisms in aborted fluids.
- Manage parturient animals in an enclosed environment with controlled airflow to lower risk for down-wind transmission. This may increase risk of seroconversion for animals housed within the same environment.
- Eliminate land application of fresh manure.
- Compost manure for 90 days before land application and transport manure and apply only on damp low-wind days.⁸⁶⁻⁸⁸
- Promptly remove and dispose of aborted fetus and uterine fluids either by closed composting or burning.
- Move naïve or gestating animals to areas of the farm that are upwind of aborting animals.
- Minimize development of excessively dry and dusty environments in animal housing areas (mist or gently wetting down dusty environments) and around barns.

Mammals, both wild and domestic, birds, and ticks can act as reservoirs of infection and also potential mechanisms of transmission.^{89,90} *Coxiella burnetii* shedding occurs from all domesticated species.⁹¹⁻⁹³ Farm dogs and farm cats commonly scavenge on and might disseminate the organism in the local environment. These non-livestock species also experience clinical abortion associated with this organism and, zoonotic disease has ensued.⁹⁴⁻⁹⁷ Infected horses, mules and donkeys in rare cases can abort.⁹⁸ *C. burnetii* shedding has been described in many species of wild animals commonly encountered on farms, including wild migratory and nonmigratory birds.⁹⁹⁻¹⁰¹ Methods to reduce risk from these species, particularly those that are reproductively active, have not been shown yet to be effective; however, it might be prudent to restrict their access to livestock whenever feasible.^{97,102,103}

6.5 | Quarantine

In many US states and other animal health jurisdictions, coxiellosis is a reportable disease. If infection and disease is documented in these jurisdictions, state animal health officials ultimately have control of regulatory actions that may be required. According to the National Association of State Public Health Veterinarians and National Assembly of State Animal Health Officials guidance document, quarantine of infected herds is "generally not recommended."²¹

TABLE 4 Characteristic of individuals that have an increased risk of zoonotic infections of *C. burnetii*²²

Condition	General principles
Occupations with the highest risk of exposure	
<ul style="list-style-type: none"> • Livestock producers, their families and employees • Slaughterhouse employees • Research laboratory animal workers handling pregnant sheep • Veterinarians • Animal health technicians • Veterinary students • Livestock service providers (nutritionist, AI technicians, shearers, livestock truckers) 	<p>Any individual in contact with parturient or early post-partum small ruminants or cats. Longer and closer exposure = higher risk. However, the public can also be at risk of exposure under specific circumstances. Some examples:</p> <ul style="list-style-type: none"> • Individuals attending agricultural exhibitions or petting zoos especially if parturient or early postpartum animals are present. • Living in close proximity to a livestock operation, particularly if sheep or goats and even more likely if parturient. Close proximity can mean up to several kilometers away. • Consumption of raw milk or raw milk cheeses cured for < 90 days. The low pH of hard cheeses will kill the bacteria.
Factors that increase risk for severe disease consequences if infected	
<ul style="list-style-type: none"> • Pre-existing cardiac valve disease • Artificial heart valves or grafts • Arterial aneurisms • Immunosuppression (including HIV, chemotherapy, or concurrent disease) • Pregnancy (*see comment) • Extremes of age (infants and geriatric) 	<p>Individuals with these factors should avoid or greatly limit contact with high-risk livestock (see Table 5)</p> <p>Infection during pregnancy is a risk for the women to develop chronic Q fever later; however, the major concern is pregnant women with Q fever are at higher risk of miscarriage/stillbirth, premature parturition and intrauterine fetal growth retardation and should receive prompt medical treatment to avoid adverse outcomes.^{16,107-111}</p>

6.6 | Using individual testing to eradicate infection from a herd/flock

Strategies focused on managing coxiellosis using an individual test and remove approach are unlikely to succeed and are not recommended because reliable, consistent identification of infected animals using the currently available diagnostic tests remains problematic. As discussed above, some serologically negative animals shed the organism, and shedding is often intermittent and inconsistent except during the parturient and immediately postparturient period making identifying all positive animals difficult by PCR. Further, the high level of environmental contamination combined with the extreme persistence of this organism in the environment allow for continued exposure and make eradication difficult.

6.7 | Depopulation and breeding ban

Facing an epidemic of human Q fever concurrent to small ruminant coxiellosis, the Netherlands utilized a multi-pronged approach to limit transmission to humans.¹⁶ In addition to vaccination, the government initiated a program to depopulate all pregnant goats on infected farms and concurrently placed a permanent breeding ban on all non-pregnant animals on infected farms that were not vaccinated before their first pregnancy.⁴³ These measures were intended to reduce the likelihood of postparturient shedding of the bacterium either from abortion or normal kidding.⁶⁸ Together with vaccination, this approach did ultimately aid in stopping the epidemic; however, questions remain regarding the necessity of the depopulation efforts.⁶⁸ Based on the epidemiologic data and our current knowledge of vaccine efficacy, use of a depopulation approach is not appropriate in most farm management plans. In agreement with this assessment, the NASPHV and NASHO guidance document states “mass euthanasia of infected herds is never warranted.”²¹

7 | ZONOTIC RISKS AND MITIGATION STRATEGIES

Diagnostic testing strategies used to identify infections in humans have been defined and discussed in detail elsewhere.²² Table 4 provides characteristics of people that have higher risks for exposure and infection. Most exposure to *C. burnetii* is via infection with the SCV form, usually through inhalation of aerosolized bacterium, although ingestion of contaminated milk products is also possible.⁷ As few as 1–10 organisms are cable of causing an infection.¹⁰⁴ Approximately half of human infections with *C. burnetii* are asymptomatic.¹⁰⁵ Acute-onset clinical disease occurs 2–6 weeks postexposure in the other half.¹⁰⁶ Most acute clinical infections results in flu-like symptoms (fever, headache, chills, sweating, and fatigue)²² Some people develop severe headaches that originate from the retro-orbital area.²² Without treatment, the febrile episodes resolve in 10–14 days and most people fully recover, although there are some that develop a post Q fever fatigue syndrome.²² However, some individuals require antibiotic treatment to recover and a small proportion of those can require hospitalization.²² Because of the nonspecific clinical signs of acute Q fever and its self-limiting course in most people, it is probably vastly underreported.²² This is supported by the high seroprevalence among people that have a high risk of infection, including veterinarians.⁶⁹⁻⁷¹ Approximately 30%–50% of patients with acute, symptomatic Q-fever develop pneumonia, while a small proportion of other develop acute hepatitis, myocarditis and meningoencephalitis.²²

Clinical disease associated with the chronic form of Q-fever occurs in <5% of people that develop acute symptomatic infections, although chronic disease has been reported in people with no history of acute symptoms.²² Chronic Q fever can develop months to years after the acute infection.^{7,22} Endocarditis and other vascular infections are the most common manifestation of chronic Q fever but can also present as chronic hepatitis, osteomyelitis, septic arthritis, and chronic pneumonia.²²

7.1 | How can people protect themselves from Q fever?

There are two approaches for protecting people from infection (in the absence of human vaccination, which is only available in Australia): avoiding situations that lead to exposure, and use of hygiene and personal protective equipment (PPE) to reduce the likelihood of infection. When possible, people with a higher risk of developing severe consequences from infection (eg, people with cardiac valvular disease, immunosuppression, and pregnancy) should consider avoiding situations associated with a higher likelihood of exposure. If this is not possible, then infection risks should be minimized by optimizing environmental hygiene, through optimal adherence to hand hygiene, and by using of PPE including gloves, protective outerwear, and respiratory protection. It is difficult to provide clear-cut recommendations regarding which people should use PPE and when and how rigorously the precautions should be applied. This is because it is clear that infection and shedding prevalences are often high in ruminants, and the seroprevalence for *C. burnetii* is high among high-risk professions (as high as 60%), but the number of documented cases of Q fever in people is relatively small.¹¹² Further, most of these clinical Q fever cases are mild and self-limiting.²² However, the severe health consequences in a small minority of clinically affected individuals means that the risks for zoonotic infections cannot be ignored. It is clear that when a documented case of Q fever in a person has epidemiological links to farm exposures, other personnel associated with that farm might have an increased risk of developing clinical Q fever in the same period, and higher levels of precautions are warranted.²¹ Thus, the risk of serious health consequences for an individual that becomes infected needs to be considered in context with the exposure risk of the situation. Concern for these circumstances is not uniform because people have varying levels of risk-aversion regarding this disease problem. As a result, infection control practices that are employed for *C. burnetii* frequently vary depending among individuals and institutions. However, there is an ethical responsibility for employers and institutions to promote awareness and education regarding risks for zoonotic infection, and to facilitate the ability for individuals to protect themselves. Thus, employers have a responsibility to make it easy and acceptable for individuals to use infection control methods that fit their individual situation and their personal level of risk-aversion.

In situations described above where exposure is likely, such as during parturition of infected small ruminants, infection can occur through inhalation of small particle aerosols. Use of eye protection such as splash shields and high efficiency respiratory protection is needed to protect workers in these situations. Surgical masks or dust masks might be helpful in preventing inhalation of larger droplets, but they are not sufficient to prevent inhalation of small particle aerosols or fine dusts. Tight fitting respirators (eg, full- or half-face canister respirators) and N95 masks should only be used by trained personnel that are medically cleared to use this type of PPE. Alternatively, powered air-purifying respirators can be worn by trained individuals without the need for fit-testing, which can increase flexibility of management protocols. Use of gloves and rigorous adherence to hand hygiene practices will help to prevent inadvertent oral exposures.

Because of risks for infection with a variety of important zoonotic agents, including *C. burnetii*, personnel involved in obstetrical procedures should also prevent skin exposures by using appropriate barrier clothing. It has also been recommended that administrative personnel providing oversight for occupational safety might want to collect and store pre-exposure serum samples to aid in diagnosis of *C. burnetii* infections, should the need arise.²²

It situations where previous testing and the health history of a flock or herd suggests that there is a low risk of *C. burnetii* infection, it might be considered reasonable to employ less rigorous infection prevention methods, especially when working on nonobstetrical health/disease problems. However, in situations where the infection status of individuals, or source flocks or herds, is unknown, it is advisable that more stringent precautions be applied because of the ubiquity of *C. burnetii*.

7.2 | Recommendations for management of animals in a veterinary hospital

Veterinary personnel caring for livestock cannot be protected from all risk of exposure to *C. burnetii*, regardless of the precautions that are employed. However, there are opportunities to mitigate risk, especially in veterinary hospital settings. As animals are admitted to a facility, the clinician should assess the risk of zoonotic exposure to *Coxiella* and should preemptively develop an individualized infection control plan for that patient. As discussed, periparturient sheep and goats have the highest risk for vaginal shedding of *C. burnetii*, especially from parturition until 2 weeks postpartum or longer. Small ruminants presenting with a history of dystocia, abortion, stillbirth or offspring that fail to thrive, have a particularly high likelihood of shedding, but these signs can also be caused by other infectious and noninfectious causes of abortion.²¹ Ruminants with no history of individual or farm level reproductive disorders can shed the organism asymptotically. It should also be noted that all domestic species have been documented to be capable of shedding the organism, so routine biosecurity measures including hand washing, eliminating storage or consumption of food and drink in animal care areas, and use of appropriate hospital-dedicated clothing should be advocated in all areas of the hospital (both large and small animal). Table 5 summarizes some characteristics that will assist veterinarians in assessing the zoonotic disease hazard posed by individual patients.

There are no published evaluations regarding the efficacy of coxiellosis management strategies in veterinary hospitals, but general principles of biosecurity and infection control should be employed in developing plans for management of this disease in hospital settings (Table 6).

7.3 | Recommendations for control of human exposures in the field

Some of the precautions that are recommended for control of exposure to *C. burnetii* in veterinary hospitals may be difficult or impossible to apply in field circumstances. Consideration of the likelihood of infection in herds/flocks, and in individual animals can provide a basis for appropriately adjusting the rigor of precautions commensurate

TABLE 5 Characteristics used to aid in the assessment of the risk of zoonotic exposure to *C. burnetii*

Risk category	Patient characteristics
Lower Risk	<ul style="list-style-type: none"> • Male ruminants. • Nonpregnant female ruminants. • Pregnant small ruminants that will be leaving the facility before parturition. • Other parturient mammals.
Intermediate Risk	<ul style="list-style-type: none"> • Periparturient small ruminants without an individual or farm level history of recent dystocia, abortion, stillbirth, or offspring that are born weak and undersized. • Periparturient cattle. • Periparturient felines that have been confined to the indoors.
Highest Risk	<ul style="list-style-type: none"> • Periparturient small ruminants from a herd/flock with a known history of coxiellosis, or from a herd/flock with a history of recent dystocia, abortion, stillbirth, or offspring that are born weak and undersized. • Periparturient felines if they have outdoor access.^{94-96,103,113,114}

with the risk of exposure. This will also facilitate easier management of animals in situations where the infection risk is low. Contact with flocks/herds that have a higher infection risk (known endemic infection status or during abortion outbreaks), and interaction with animals in key shedding circumstances (eg, contact during periparturient events) should trigger use of more rigorous prevention methods.

Frequent contact with animals or their environments increases the risk for a variety of zoonotic infections. As such, it is always advisable to use separate clothing for activities involving contact with livestock and to change out of this clothing before returning to a person's home, areas where food is prepared or consumed, and before contacting individuals that have increased risks for zoonotic infections (eg, young children, elderly, etc). Strict attention to hand hygiene will also decrease risks for zoonotic infections, particularly before any hand-to-face contact (eg, eating, smoking, etc), before and after animal contact, and before returning to vehicles or home.

Infection principally occurs through inhalation or ingestion. Prevention strategies should counter these types of exposures to prevent anthropogenic transmission to people and animals. Use of water impervious protective outer attire (ie, barrier gowns) that is disposable or facilitates cleaning and disinfection between contact with different animals will help to prevent transmission when working with periparturient animals. These items should be changed or cleaned and disinfected changed after working with periparturient animals or their environments (eg, cleaning) and when exiting the livestock-rearing facilities. As discussed previously, rigorous attention to hand hygiene and appropriate use of eye and respiratory protection are essential to prevent human infections in high infection risk circumstances. Veterinary personnel and producers should consult with an occupational health physician before employing any type of respirator.

Where possible, it is also important to dispose of the afterbirth and contaminated bedding shortly after parturition to minimize

TABLE 6 Biosecurity measures that should be considered for inclusion based on the risk posed by different types of patients

Risk category	Possible infection control and biosecurity measures that should be considered
Lower Risk	<ul style="list-style-type: none"> • Assurance of personnel training on clinical signs of Q fever and how to mitigate their risk. The NASPHV document provides some good materials for this process, especially Appendix 2: Q Fever Factsheet and Appendix 3: Personal Protective Actions & Equipment for Animal Owners, Caretakers.²¹ In addition, these individuals should be instructed to immediately seek medical attention if they develop symptoms consistent with Q fever and that they should specifically notify their physician of a potential exposure. • General best practice hospital biosecurity measures including: Use of dedicated clothing and footwear on the clinic floor that does not leave the hospital, use of standard barrier precautions at all times and frequent thorough hand washing after handling animals and excluding food and drink from animal housing areas.
Intermediate Risk	<p>Above precautions plus:</p> <ul style="list-style-type: none"> • When performing procedures involving reproductive fluid and tissues, veterinary personnel should use disposable plastic sleeves and/or gloves and either a face shield or protective eyewear and respiratory protection (see discussion regarding use of respirators). • All reproductive tissues (placenta) and bedding contaminated with amniotic and allantoic fluids should be removed as soon as possible, handling and disposing in a manner that prevents further exposure to humans or animals, as well as preventing environmental contamination. • Personnel with known risk factors for Q fever should be excluded from exposure to these animal care situations. • Personnel exposed to animals considered to have a greater risk of shedding <i>C. burnetii</i> should seek medical attention if they develop signs related to Q-fever (including fever or flu-like illness).
Highest Risk	<p>Above precautions plus:</p> <ul style="list-style-type: none"> • Patients that have a high likelihood of shedding <i>C. burnetii</i> should be managed separately from other susceptible animals in areas of facilities that have separate ventilation and are easy to clean and disinfect. This might be easiest to achieve in a separate facility such as an isolation facility. • Because human infection can result from exposure to contaminated droplets, small particle aerosols, and dusts, use of eye protection (eg, face shields) and respiratory protection should be facilitated and encouraged, if not required. Respirators must only be used after appropriate training, medical clearance, and fit testing. • Personnel exposed to animals that should monitor themselves for signs of infection (eg, fever, flu-like illness, etc). Maintaining a daily log of body temperature may be recommended for people with highest likelihood of exposure and infection, especially if they have risk factors for severe Q-fever.²² People that develop any signs of illness should seek advice from a healthcare professional.

TABLE 7 Disinfectants that have demonstrated at least some level of efficacy in deactivating *C. burnetii* and could be used in veterinary facilities or farms

Product	Level of efficacy and reference
Quaternary ammonium/detergent (MicroChem-Plus)	Complete inactivation after a 30 minutes contact time. ²²
70% Ethanol	Complete inactivation after a 30 minutes contact time, but requires frequent reapplication because of rapid evaporation. ¹¹⁶
1% Peroxygen (Virkon S)	>90% reduction in infectivity after a 30 minutes contact time. ^{118,119}
1:100 dilution of hypochlorite	>90% reduction in infectivity after a 30 minutes contact time. ^{118,119}

NOTE: All organic matter should be removed before cleaning, and proper PPE should be worn during cleaning.

environmental contamination and prevention of human and animal exposures. Even in situations where circumstances prevent complete cleaning, best efforts should be made to remove contaminated materials. When possible, cleaning with detergents and water, followed by use of disinfectants should be employed. Guidelines for cleaning and disinfection best practices have been previously published.¹¹⁵ Recommendations regarding disinfection are described below. Routine cleaning and disinfection of lambing/kidding pens has been demonstrated to be associated with a lower risk of human seroconversion in producers.^{64,65} During this cleaning on farms with documented coxiellosis it is recommended that a fit tested N95 mask be used, and essential if another individual developed Q fever. In addition, farm personnel that are pregnant or are otherwise at higher risk of developing Q fever based on the description above should consider taking a higher level of precautions, including using a fit tested N95 mask.

7.4 | Recommendations for management of animals used in veterinary teaching

For teaching laboratories involving small ruminants, use male and nonpregnant females that have not given birth in the previous 2 months.²² Use of animals with impending parturition or early postpartum small ruminants for elective teaching exercises should be limited where possible.

7.5 | Disinfection

The SCV is highly resistant to many commercially available disinfectants as well as heat, pressure and drying.¹¹⁶⁻¹¹⁹ Therefore, removal of contaminated materials (eg, bedding) through standard cleaning protocols likely provides the most immediate benefit and may lower the level of bacteria in the environment. Scrubbing with detergents and rinsing with copious amounts of water (when possible) should be emphasized whenever possible as a means to reduce the environmental load of infectious organisms. However, care should be taken to prevent aerosolization through use of high pressure washers or moving of bedding using leaf blowers and pressure washers, and personnel should use appropriate PPE during cleaning and disinfection. There is little published research regarding the efficacy of cleaning and disinfection processes, but Table 7 provides a list of some possible disinfectant options that may provide better efficacy.

implications related to *C. burnetii* infections, a number of issues still need to be addressed. The authors of this report believe that the following actions should be prioritized by scientists, regulators and other government officials.

- Considered the highest priority by this consensus panel is the need to develop, validate, and license an effective *C. burnetii* vaccine(s) for use in livestock as an aid for controlling coxiellosis in North America. To be useful, the vaccine should prevent reproductive losses, and very importantly minimize shedding of infectious organisms to the greatest extent possible. As described above, vaccines that use phase 1 antigens are the best tool (and in many cases the only reasonable tool) for managing coxiellosis in animals. The low efficacy of antibiotic treatment, coupled with the difficulty associated with providing effective biosecurity for a highly infectious airborne pathogen, severely limits the ability of veterinary and public health officials to effectively manage coxiellosis.
- Providing access to an effective and safe vaccine for humans is also important to prevent disease among people with a high risk of exposure or high risks for severe disease consequences. There are no vaccines approved for use in humans in North America, but there is a phase 1 strain whole cell *C. burnetii* vaccine that is commercially available in Australia (Q-Vax, CSL). It is routinely used for people working in high-risk occupations, including veterinarians and veterinary students. This vaccine has been shown to be effective in preventing Q fever disease when administered to people documented to be seronegative.^{120,121} Importantly, people that have been exposed to *C. burnetii* before vaccination can suffer from local and occasionally severe systemic adverse effects.
- There is a need for additional research related to the role of antibiotics in the management and control of abortions and pathogen shedding in livestock. The human literature suggest that antibiotic treatment can be effective in control and eliminating pathogen shedding in humans; however, similar responses have not been observed in ruminants (see section above).
- To allow for improved disinfection of hospital facilities there is a need for additional work focused on the development of effective bacteriocidal products and applications.
- There is a critical need for the development of novel testing approaches that can identify animals that are subclinically infected with coxiella before parturition. At present, none of the available diagnostic assays allow the reliable pre-parturient detection of animals that will shed organism at parturition. This greatly hampers biosecurity control measures and increases human risk of exposure.

8 | FUTURE DIRECTIONS

While scientists have made important strides during the last decade in improving our understanding of the animal and human health

- While currently technically challenging and not widely available, genotyping of clinical coxiella isolates holds great potential to improve our understanding of coxiella epidemiology and transmission. Additional efforts in this area may improve our understanding of the role of genotypic similarity or differences in animal reservoirs of infection and continue to build our understanding of the difference in zoonotic risk associated with different genotypes.

CONFLICT OF INTEREST DECLARATION

P. Plummer: National Association of State Public Health Veterinarians paid expenses and a per diem to serve on their consensus guidance panel related to Coxiellosis and the public health response.

P. Menzies: Member of the Q fever committee (unpaid) for the National Association State Public Health Veterinarians (2012-13). Invited to participate in a Q fever Roundtable group for Interactive Forums Inc. Conducted research from 2010 through 2013 on prevalence of Coxiella burnetii infection in sheep flocks and goat herds in Ontario and their farm workers, associated risk factors and potential adverse effects on flock productivity and human health. The funding agencies were Animal Health Surveillance Initiative – OMAFRA U of Guelph Agreement, Ontario Ministry of Health and Long-Term Care. The project was part of activities as an academic research. Conducted research from 2013 through 2015 on prevalence and strain identification of Coxiella burnetii on dairy goat farms and in associated wildlife. The funding agencies were Emergency Management – OMAFRA U of Guelph Research Program, Centre for Goat Research & Innovation (funds from the Ontario government), Canada Research Chair (NSERC) Funds Laurentian University Canada.

P. Morley: Paid consultant for Mississippi State University, University of Georgia, North Carolina State University, Washington State University, and University of Pretoria on infection control in veterinary hospitals.

R. van den Brom: Conducted research for Dutch government from 2008 through 2012. Employed in research for GD Animal Health.

OFF-LABEL ANTIMICROBIAL DECLARATION

Authors declare no off-label use of antimicrobials.

INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION

Authors declare no IACUC or other approval was needed.

ORCID

Paul J. Plummer  <http://orcid.org/0000-0002-5784-8382>

REFERENCES

- Derrick EH. Q fever, a new fever entity: Clinical features, diagnosis and laboratory investigation. *Med J Aust.* 1937;2.
- Philip C. Comments on the name of the Q fever organism. *Public Health Rep.* 1948;63:58.
- Arricau-Bouvery N, Rodolakis A. Is Q fever an emerging or reemerging zoonosis? *Vet Res.* 2005;36:327–349.
- Prevention. CfDca. Q fever—California. *Morb Mortal Wkly Rep.* 1977; 86–87.
- Editorial comment on Q fever transmitted by blood transfusion – United States. *Cur Dis Wkly Rep.* 1977;3:210.
- Roest HJ, van Gelderen B, Dinkla A, et al. Q fever in pregnant goats: Pathogenesis and excretion of Coxiella burnetii. *PLoS One.* 2012;7: e48949.
- Angelakis E, Raoult D. Q Fever. *Vet Microbiol.* 2010;140:297–309.
- Kersh GJ, Wolfe TM, Fitzpatrick KA, et al. Presence of Coxiella burnetii DNA in the Environment of the United States, 2006 to 2008. *Appl Environ Microbiol.* 2010;76:4469–4475.
- Astobiza I, Barandika JF, Ruiz-Fons F, et al. Coxiella burnetii shedding and environmental contamination at lambing in two highly naturally-infected dairy sheep flocks after vaccination. *Res Vet Sci.* 2011;91: e58–e63.
- Astobiza I, Barandika JF, Ruiz-Fons F, et al. Four-year evaluation of the effect of vaccination against Coxiella burnetii on reduction of animal infection and environmental contamination in a naturally infected dairy sheep flock. *Appl Environ Microbiol.* 2011;77: 7405–7407.
- de Bruin A, de Groot A, de Heer L, et al. Detection of Coxiella burnetii in complex matrices by using multiplex quantitative PCR during a major Q fever outbreak in The Netherlands. *Appl Environ Microbiol.* 2011;77:6516–6523.
- de Bruin A. Q fever: The answer is blowing in the wind: Detection of Coxiella burnetii in aerosols. RIVM rapport 330291005. Bilthoven, Netherlands: National Institute for Public Health and the Environment ; 2011.
- Wallensten A, Moore P, Webster H, et al. Q fever outbreak in Cheltenham, United Kingdom, in 2007 and the use of dispersion modelling to investigate the possibility of airborne spread. *Euro Surveill.* 2010;15.
- van der Hoek W, Hunink J, Vellema P, Droogers P. Q fever in The Netherlands: the role of local environmental conditions. *Int J Environ Health Res.* 2011;21:441–451.
- Dijkstra F, Hoek W, Wijers N, et al. The 2007–2010 Q fever epidemic in the Netherlands: characteristics of notified acute Q fever patients and the association with dairy goat farming. *FEMS Immunol Med Microbiol.* 2011;64(1):3–12.
- van der Hoek W, Morroy G, Renders NH, et al. Epidemic Q fever in humans in the Netherlands. *Adv Exp Med Biol.* 2012;984:329–364.
- Centers for Disease C, Prevention. Notes from the field: Q fever outbreak associated with goat farms—Washington and Montana, 2011. *Morb Mortal Wkly Rep.* 2011;60:1393.
- Bond KA, Vincent G, Wilks CR, et al. One Health approach to controlling a Q fever outbreak on an Australian goat farm. *Epidemiol Infect.* 2016;144:1129–1141.
- Georgiev M, Afonso A, Neubauer H, et al. Q fever in humans and farm animals in four European countries, 1982 to 2010. *Euro Surveill.* 2013;18.
- Hatchette TF, Hudson RC, Schlech WF, et al. Goat-associated Q fever: a new disease in Newfoundland. *Emerg Infect Dis.* 2001;7: 413–419.
- Garvey A, Szymanski T, Anderson A, et al. Prevention and Control of Coxiella burnetii Infection among Humans and Animals: Guidance for a Coordinated Public Health and Animal Health Response. *National Association of State Public Health Veterinarians;* 2013.
- Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever—United States, 2013: Recommendations from CDC and the Q Fever Working Group. *MMWR Recomm Rep.* 2013;62:1–30.
- USDA. Evaluation of factors that would initiate or propagate epidemic coxiellosis in the U.S. domesticated goat population. Fort Collins, CO: USDA:APHIS:VS:Centers for Epidemiology and Animal Health; 2013.
- OIE. OIE Terrestrial Manual. OIE-World Organisation for Animal Health; 2015. <http://www.oie.int/standard-setting/terrestrial-manual/access-online/>

25. Mori M, Boarbi S, Michel P, et al. In Vitro and in vivo Infectious Potential of *Coxiella burnetii*: A Study on Belgian Livestock Isolates. *Plos One*. 2013;8:e67622.
26. Hansen MS, Rodolakis A, Cochonneau D, et al. *Coxiella burnetii* associated placental lesions and infection level in parturient cows. *Vet J*. 2011;190:e135–e139.
27. Sidi-Boumedine K, Rousset E, Henning K, et al. Development of harmonised schemes for the monitoring and reporting of Q-fever in animals in the European Union. EFS; 2010. <https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/sp.efsa.2010.EN-48>
28. Roest HI, Bossers A, Rebel JM. Q fever diagnosis and control in domestic ruminants. *Dev Biol (Basel)*. 2013;135:183–189.
29. Van den Brom R, van Engelen E, Roest HI, et al. *Coxiella burnetii* infections in sheep or goats: An opinionated review. *Vet Microbiol*. 2015;181:119–129.
30. Rodolakis A, Berri M, Hechard C, et al. Comparison of *Coxiella burnetii* shedding in milk of dairy bovine, caprine, and ovine herds. *J Dairy Sci*. 2007;90:5352–5360.
31. Sting R, Molz K, Philipp W, et al. Quantitative real-time PCR and phase specific serology are mutually supportive in Q fever diagnostics in goats. *Vet Microbiol*. 2013;167:600–608.
32. Rousset E, Durand B, Berri M, et al. Comparative diagnostic potential of three serological tests for abortive Q fever in goat herds. *Vet Microbiol*. 2007;124:286–297.
33. Emery MP, Ostlund EN, Ait Ichou M, et al. *Coxiella burnetii* serology assays in goat abortion storm. *J Vet Diagn Invest*. 2014;26:141–145.
34. Emery MP, Ostlund EN, Schmitt BJ. Comparison of Q fever serology methods in cattle, goats, and sheep. *J Vet Diagn Invest*. 2012;24:379–382.
35. Nogareda C, Almeria S, Serrano B, et al. Dynamics of *Coxiella burnetii* antibodies and seroconversion in a dairy cow herd with endemic infection and excreting high numbers of the bacterium in the bulk tank milk. *Res Vet Sci*. 2012;93:1211–1212.
36. Navarro JA, Ortega N, Buendia AJ, et al. Diagnosis of placental pathogens in small ruminants by immunohistochemistry and PCR on paraffin-embedded samples. *Vet Rec*. 2009;165:175–178.
37. van den Brom R, Lievaart-Peterson K, Luttikholt S, et al. Abortion in small ruminants in the Netherlands between 2006 and 2011. *Tijdschr Diergeneeskd*. 2012;137:450–457.
38. Hazlett MJ, McDowall R, DeLay J, et al. A prospective study of sheep and goat abortion using real-time polymerase chain reaction and cut point estimation shows *Coxiella burnetii* and *Chlamydia abortus* infection concurrently with other major pathogens. *J Vet Diagn Invest*. 2013;25:359–368.
39. de Cremoux R, Rousset E, Touratier A, et al. *Coxiella burnetii* vaginal shedding and antibody responses in dairy goat herds in a context of clinical Q fever outbreaks. *FEMS Immunol Med Microbiol*. 2012;64:120–122.
40. Guatteo R, Joly A, Beaudeau F. Shedding and serological patterns of dairy cows following abortions associated with *Coxiella burnetii* DNA detection. *Vet Microbiol*. 2012;155:430–433.
41. Rousset E, Berri M, Durand B, et al. *Coxiella burnetii* shedding routes and antibody response after outbreaks of Q fever-induced abortion in dairy goat herds. *Appl Environ Microbiol*. 2009;75:428–433.
42. Arricau Bouvery N, Souriau A, Lechopier P, et al. Experimental *Coxiella burnetii* infection in pregnant goats: excretion routes. *Vet Res*. 2003;34:423–433.
43. Van den Brom R, Santman-Berends I, Luttikholt S, et al. Bulk tank milk surveillance as a measure to detect *Coxiella burnetii* shedding dairy goat herds in the Netherlands between 2009 and 2014. *J Dairy Sci*. 2015;98:3814–3825.
44. Berri M, Souriau A, Crosby M, et al. Relationships between the shedding of *Coxiella burnetii*, clinical signs and serological responses of 34 sheep. *Vet Rec*. 2001;148:502–505.
45. Serrano-Perez B, Almeria S, Tutusaus J, et al. *Coxiella burnetii* total immunoglobulin G, phase I and phase II immunoglobulin G antibodies, and bacterial shedding in young dams in persistently infected dairy herds. *J Vet Diagn Invest*. 2015;27:167–176.
46. Pinero A, Ruiz-Fons F, Hurtado A, et al. Changes in the dynamics of *Coxiella burnetii* infection in dairy cattle: an approach to match field data with the epidemiological cycle of *C. burnetii* in endemic herds. *J Dairy Sci*. 2014;97:2718–2730.
47. Hogerwerf L, Koop G, Klinkenberg D, et al. Test and cull of high risk *Coxiella burnetii* infected pregnant dairy goats is not feasible due to poor test performance. *Vet J*. 2014;200:343–345.
48. Bottcher J, Vossen A, Janowetz B, et al. Insights into the dynamics of endemic *Coxiella burnetii* infection in cattle by application of phase-specific ELISAs in an infected dairy herd. *Vet Microbiol*. 2011;151:291–300.
49. Natale A, Bucci G, Capello K, et al. Old and new diagnostic approaches for Q fever diagnosis: correlation among serological (CFT, ELISA) and molecular analyses. *Comp Immunol Microbiol Infect Dis*. 2012;35:375–379.
50. Niemczuk K, Szymańska-Czerwińska M, Śmietanka K, et al. Comparison of diagnostic potential of serological, molecular and cell culture methods for detection of Q fever in ruminants. *Vet Microbiol*. 2014;171:147–152.
51. Bauer AE, Hubbard KRA, Johnson AJ, et al. A cross sectional study evaluating the prevalence of *Coxiella burnetii*, potential risk factors for infection, and agreement between diagnostic methods in goats in Indiana. *Prev Vet Med*. 2016;126:131–137.
52. Taurel AF, Guatteo R, Joly A, et al. Relationship between the level of antibodies in bulk tank milk and the within-herd seroprevalence of *Coxiella burnetii* in cows. *Epidemiol Infect*. 2012;140:1710–1713.
53. Ruiz-Fons F, Astobiza I, Barandika JF, et al. Measuring antibody levels in bulk-tank milk as an epidemiological tool to search for the status of *Coxiella burnetii* in dairy sheep. *Epidemiol Infect*. 2011;139:1631–1636.
54. van den Brom R, van Engelen E, Luttikholt S, et al. *Coxiella burnetii* in bulk tank milk samples from dairy goat and dairy sheep farms in The Netherlands in 2008. *Vet Rec*. 2012;170:310.
55. Martin SW, Shoukri M, Thorburn MA. Evaluating the health status of herds based on tests applied to individuals. *Prev Vet Med*. 1992;14:33–43.
56. van den Brom R, van Engelen E, Vos J, et al. Detection of *Coxiella burnetii* in the bulk tank milk from a farm with vaccinated goats, by using a specific PCR technique. *Small Rumin Res*. 2013;110:150–154.
57. Eibach R, Bothe F, Runge M, et al. Q fever: baseline monitoring of a sheep and a goat flock associated with human infections. *Epidemiol Infect*. 2012;140:1939–1949.
58. Schimmer B, Schegget R, Wegdam M, et al. The use of a geographic information system to identify a dairy goat farm as the most likely source of an urban Q-fever outbreak. *BMC Infect Dis*. 2010;10.
59. Guatteo R, Beaudeau F, Joly A, et al. *Coxiella burnetii* shedding by dairy cows. *Vet Res*. 2007;38:849.
60. Garcia-Perez AL, Astobiza I, Barandika JF, et al. Investigation of *Coxiella burnetii* occurrence in dairy sheep flocks by bulk tank milk analysis and antibody level determination. *J Dairy Sci*. 2009;92:1581.
61. de Bruin A, van Alphen PT, van der Plaats RQ, et al. Molecular typing of *Coxiella burnetii* from animal and environmental matrices during Q fever epidemics in the Netherlands. *BMC Vet Res*. 2012;8:165.
62. Eisenberg SW, Nielen M, Santema W, Houwers DJ, Heederik D, Koets AP. Detection of spatial and temporal spread of *Mycobacterium avium* subsp. *paratuberculosis* in the environment of a cattle farm through bio-aerosols. *Vet Microbiol*. 2010;143:284–292.
63. van Engelen E, Luttikholt S, Peperkamp K, Vellema P, Van den Brom R. Small ruminant abortions in The Netherlands during lambing season 2012–2013. *Vet Rec*. 2014;174:506.
64. Meadows S, Jones-Bitton A, McEwen S, et al. *Coxiella burnetii* seropositivity and associated risk factors in sheep in Ontario, Canada. *Prev Vet Med*. 2015;122:129–134.
65. Meadows S, Jones-Bitton A, McEwen S, et al. *Coxiella burnetii* seropositivity and associated risk factors in goats in Ontario, Canada. *Prev Vet Med*. 2015;121:199–205.
66. Schimmer B, Luttikholt S, Hautvast JL, Graat EA, Vellema P, Duynhoven YT. Seroprevalence and risk factors of Q fever in goats on commercial dairy goat farms in the Netherlands, 2009–2010. *BMC Vet Res*. 2011;7:81.
67. Van den Brom R, Moll L, van Schaik G, Vellema P. Demography of Q fever seroprevalence in sheep and goats in The Netherlands in 2008. *Prev Vet Med*. 2013;109:76–82.

68. Hogerwerf L, van den Brom R, Roest HI, et al. Reduction of *Coxiella burnetii* prevalence by vaccination of goats and sheep, The Netherlands. *Emerg Infect Dis*. 2011;17:379–386.
69. Guatteo R, Seegers H, Joly A, Beaudeau F. Prevention of *Coxiella burnetii* shedding in infected dairy herds using a phase I *C. burnetii* inactivated vaccine. *Vaccine*. 2008;26:4320–4328.
70. Courcoul A, Vergu E, Denis JB, Beaudeau F. Spread of Q fever within dairy cattle herds: Key parameters inferred using a Bayesian approach. *Proc Biol Sci*. 2010;277:2857–2865.
71. Taurel AF, Guatteo R, Lehebel A, Joly A, Beaudeau F. Vaccination using phase I vaccine is effective to control *Coxiella burnetii* shedding in infected dairy cattle herds. *Comp Immunol Microbiol Infect Dis*. 2014;37:1–9.
72. Eibach R, Bothe F, Runge M, Ganter M. Long-term monitoring of a *Coxiella burnetii*-infected sheep flock after vaccination and antibiotic treatment under field conditions. *Berl Munch Tierarztl Wochenschr*. 2013;126:3–9.
73. Washburn K, Fajt VR, Plummer P, Coetzee JF, Wulf LW, Washburn S. Pharmacokinetics of oral chlortetracycline in nonpregnant adult ewes. *J Vet Pharmacol Ther*. 2014;37:607–610.
74. Washburn K, Fajt VR, Plummer P, et al. Concentrations of Chlortetracycline in Fetal Tissues Following Oral Administration in the Ewe. Denver, Colorado: American College of Veterinary Internal Medicine Forum; 2016.
75. Berri M, Souriau A, Crosby M, Rodolakis A. Shedding of *Coxiella burnetii* in ewes in two pregnancies following an episode of *Coxiella* abortion in a sheep flock. *Vet Microbiol*. 2002;85:55–60.
76. Wouda W, Dercksen DP. [Abortion and stillbirth among dairy goats as a consequence of *Coxiella burnetii*]. *Tijdschr Diergeneeskd*. 2007;132:908–911.
77. Astobiza I, Barandika JF, Juste RA, Hurtado A, García-Pérez AL. Evaluation of the efficacy of oxytetracycline treatment followed by vaccination against Q fever in a highly infected sheep flock. *Vet J*. 2013;196:81–85.
78. Taurel AF, Guatteo R, Joly A, Beaudeau F. Effectiveness of vaccination and antibiotics to control *Coxiella burnetii* shedding around calving in dairy cows. *Vet Microbiol*. 2012;159:432–437.
79. Bontje DM, Backer JA, Hogerwerf L, Roest HIJ, van Roermund HJW. Analysis of Q fever in Dutch dairy goat herds and assessment of control measures by means of a transmission model. *Prev Vet Med*. 2016;123:71–89.
80. de Cremoux R, Rousset E, Touratier A, et al. Assessment of vaccination by a phase I *Coxiella burnetii*-inactivated vaccine in goat herds in clinical Q fever situation. *FEMS Immunol Med Microbiol*. 2012;64:104–106.
81. Berri M, Rousset E, Hechard C, et al. Progression of Q fever and *Coxiella burnetii* shedding in milk after an outbreak of enzootic abortion in a goat herd. *Vet Rec*. 2005;156:548–549.
82. Sandoz KM, Popham DL, Beare PA, et al. Transcriptional profiling of *Coxiella burnetii* reveals extensive cell wall remodeling in the small cell variant developmental form. *PLoS One*. 2016;11:e0149957.
83. Tissot-Dupont H, Torres S, Nezri M, Raoult D. Hyperendemic focus of Q fever related to sheep and wind. *Am J Epidemiol*. 1999;150:67–74.
84. Tissot-Dupont H, Amadei MA, Nezri M, Raoult D. A pedagogical farm as a source of Q fever in a French city. *Eur J Epidemiol*. 2005;20:957–961.
85. Arricau-Bouvery N, Souriau A, Lechopier P, Rodolakis A. Excretion of *Coxiella burnetii* during an experimental infection of pregnant goats with an abortive goat strain CbC1. *Ann N Y Acad Sci*. 2003;990:524–526.
86. de Bruin A, van der Plaats RQ, de Heer L, et al. Detection of *Coxiella burnetii* DNA on small-ruminant farms during a Q fever outbreak in the Netherlands. *Appl Environ Microbiol*. 2012;78:1652–1657.
87. Berri M, Rousset E, Champion JL, et al. Ovine manure used as a garden fertiliser as a suspected source of human Q fever. *Vet Rec*. 2003;153:269–270.
88. Hermans T, Jeurissen L, Hackert V, Hoebe C. Land-applied goat manure as a source of human Q-fever in the Netherlands, 2006–2010. *PLoS One*. 2014;9:e96607.
89. Astobiza I, Barral M, Ruiz-Fons F, Gerrikagoitia X, Hurtado A, García-Pérez AL. Molecular investigation of the occurrence of *Coxiella burnetii* in wildlife and ticks in an endemic area. *Vet Microbiol*. 2011;147:190–194.
90. Reusken C, van der Plaats R, Opsteegh M, de Bruin A, Swart A. *Coxiella burnetii* (Q fever) in *Rattus norvegicus* and *Rattus rattus* at livestock farms and urban locations in the Netherlands; could *Rattus* spp. represent reservoirs for (re)introduction? *Prev Vet Med*. 2011;101:124–130.
91. Thompson M, Mykytczuk N, Gooderham K, et al. Prevalence of the bacterium *Coxiella burnetii* in wild rodents from a Canadian natural environment park. *Zoonoses Public Health*. 2012;59:553–560.
92. Buhariwalla F, Cann B, Marrie TJ. A dog-related outbreak of Q fever. *Clin Infect Dis*. 1996;23:753–755.
93. Cairns K, Brewer M, Lappin MR. Prevalence of *Coxiella burnetii* DNA in vaginal and uterine samples from healthy cats of north-central Colorado. *J Feline Med Surg*. 2007;9:196–201.
94. Goyette M, Poirier A, Bouchard J, Morrier E. Q fever in Quebec (1989-93): Report of 14 cases. *Can J Infect Dis*. 1994;5:113–118.
95. Kopecny L, Bosward KL, Shapiro A, Norris JM. Investigating *Coxiella burnetii* infection in a breeding cattery at the centre of a Q fever outbreak. *J Feline Med Surg*. 2013;15:1037–1045.
96. Langley JM, Marrie TJ, Covert A, Waag DM, Williams JC. Poker players' pneumonia. An urban outbreak of Q fever following exposure to a parturient cat. *N Engl J Med*. 1988;319:354–356.
97. Tozer SJ, Lambert SB, Strong CL, Field HE, Sloots TP, Nissen MD. Potential animal and environmental sources of Q fever infection for humans in Queensland. *Zoonoses Public Health*. 2014;61:105–112.
98. Marenzoni ML, Stefanetti V, Papa P, et al. Is the horse a reservoir or an indicator of *Coxiella burnetii* infection? Systematic review and biomolecular investigation. *Vet Microbiol*. 2013;167:662–669.
99. Fernandez-Aguilar X, Cabezon O, Colom-Cadena A, Lavin S, López-Olvera JR. Serological survey of *Coxiella burnetii* at the wildlife-livestock interface in the Eastern Pyrenees, Spain. *Acta Vet Scand*. 2016;58:26.
100. Cumbassa A, Barahona MJ, Cunha MV, et al. *Coxiella burnetii* DNA detected in domestic ruminants and wildlife from Portugal. *Vet Microbiol*. 2015;180:136–141.
101. Candela MG, Caballol A, Atance PM. Wide exposure to *Coxiella burnetii* in ruminant and feline species living in a natural environment: Zoonoses in a human-livestock-wildlife interface. *Epidemiol Infect*. 2017;145:478–481.
102. Egberink H, Addie D, Belak S, et al. *Coxiellosis*/Q fever in cats: ABCD guidelines on prevention and management. *J Feline Med Surg*. 2013;15:573–575.
103. Fujishiro MA, Scorza AV, Gookin JL, et al. Evaluation of associations among *Coxiella burnetii* and reproductive abnormalities in cats. *J Feline Med Surg*. 2016;18:344–347.
104. Jones RM, Nicas M, Hubbard AE, et al. The Infectious Dose of *Coxiella Burnetii* (Q Fever). *Appl Biosaf*. 2006;11:32–41.
105. Maurin M, Raoult D. Q Fever. *Clin Microbiol Rev*. 1999;12:518–553.
106. van Schaik EJ, Chen C, Mertens K, Weber MM, Samuel JE. Molecular pathogenesis of the obligate intracellular bacterium *Coxiella burnetii*. *Nat Rev Microbiol*. 2013;11:561–573.
107. Raoult D, Tissot-Dupont H, Foucault C, et al. Q fever 1985–1998. Clinical and epidemiologic features of 1,383 infections. *Medicine (Baltimore)*. 2000;79:109–123.
108. Nielsen SY, Andersen AM, Molbak K, et al. No excess risk of adverse pregnancy outcomes among women with serological markers of previous infection with *Coxiella burnetii*: Evidence from the Danish National Birth Cohort. *BMC Infect Dis*. 2013;13:87.
109. Nielsen SY, Hjollund NH, Andersen AM, et al. Presence of antibodies against *Coxiella burnetii* and risk of spontaneous abortion: A nested case-control study. *PLoS One*. 2012;7:e31909.
110. Nielsen SY, Molbak K, Henriksen TB, Krogfelt KA, Larsen CS, Villumsen S. Adverse pregnancy outcomes and *Coxiella burnetii* antibodies in pregnant women, Denmark. *Emerg Infect Dis*. 2014;20:925–931.
111. Wegdam-Blans MC, Wielders CC, Meekelenkamp J, et al. Evaluation of commonly used serological tests for detection of *Coxiella burnetii*

- antibodies in well-defined acute and follow-up sera. *Clin Vaccine Immunol.* 2012;19:1110–1115.
112. Meadows S, Jones-Bitton A, McEwen SA, et al. Coxiella burnetii (Q Fever) Seropositivity and Associated Risk Factors in Sheep and Goat Farm Workers in Ontario, Canada. *Vector Borne Zoonotic Dis.* 2016;16:643–649.
 113. Shapiro AJ, Bosward KL, Heller J, et al. Seroprevalence of Coxiella burnetii in domesticated and feral cats in eastern Australia. *Vet Microbiol.* 2015;177:154–161.
 114. Meredith AL, Cleaveland SC, Denwood MJ, Brown JK, Shaw DJ. Coxiella burnetii (Q-Fever) Seroprevalence in Prey and Predators in the United Kingdom: Evaluation of Infection in Wild Rodents, Foxes and Domestic Cats Using a Modified ELISA. *Transbound Emerg Dis.* 2015;62:639–649.
 115. Morley P, Weese J. Biosecurity and infection control for large animal practices. In: BP Smith, ed. *Large Animal Internal Medicine*, 5th ed. New York: Elsevier; 2015:1407–1431.
 116. Scott GH, Williams JC. Susceptibility of Coxiella burnetii to chemical disinfectants. *Ann N Y Acad Sci.* 1990;590:291–296.
 117. Malloch RA, Stoker MG. Studies on the susceptibility of Rickettsia burneti to chemical disinfectants, and on techniques for detecting small numbers of viable organisms. *J Hyg.* 1952;50:502–514.
 118. Priestley R. Decontamination issues with Coxiella burnetii: an evaluation of currently available disinfectants. American Society of Rickettsiology 21st Meeting; Colorado Springs, CO; 2007.
 119. Banazis M. Development of tools for surveillance of Coxiella burnetii in domestic ruminants and Australian marsupials and their waste. *School of Veterinary and Biomedical Sciences Division of Health Sciences.* Murdoch, Australia: Murdoch University; 2009.
 120. Gidding HF, Wallace C, Lawrence GL, McIntyre PB. Australia's national Q fever vaccination program. *Vaccine* 2009;27:2037–2041.
 121. Marmion B. Q fever: The long journey to control by vaccination. *Med J Aust.* 2007;186:164–166.

How to cite this article: Plummer PJ, McClure J, Menzies P, Morley PS, Van den Brom R, Van Metre DC. Management of *Coxiella burnetii* infection in livestock populations and the associated zoonotic risk: A consensus statement. *J Vet Intern Med.* 2018;32:1481–1494. <https://doi.org/10.1111/jvim.15229>

© 2018. This work is published under
<http://creativecommons.org/licenses/by-nc/4.0/>(the “License”).
Notwithstanding the ProQuest Terms and Conditions, you may use this
content in accordance with the terms of the License.